GAAP revenue reached $649.1 million in Q2 2025, beating estimates by 5.7% and growing 32.9% year over year. Gross margin (GAAP) expanded to 69.7%, while International Omnipod sales grew 45% (GAAP).

The proposal would introduce competitive bidding for insulin pumps and change how Medicare pays for durable medical equipment ...

Insulet stock surged Thursday after the insulin pump-maker walloped second-quarter forecasts and raised its sales guidance for the year.

Insulet beats Q2 estimates with strong Omnipod growth and lifts 2025 revenue outlook on rising adoption and expanding global ...

Thanks to a series of equity and debt offerings, Insulet has managed to buy time in the race to expand its sales base and reach profitability before running out of cash. As of the end of December, ...

Makers of insulin delivery systems, Tandem Diabetes Care (NASDAQ:TNDM) and Insulet (NASDAQ:PODD), marked a contrasting stock ...

Insulet (Nasdaq:PODD) shares ticked up before hours today on second-quarter results that came in ahead of the consensus ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three ...

She may be small, but her voice is powerful. 4-year-old Skye Blue was diagnosed with Type 1 diabetes before she even started ...

Hundreds of billions of dollars in cuts to federal health care spending, passed last month as part of President Donald ...

Getting your Trinity Audio player ready... Lawmakers are requiring school boards across the state, including the Beaufort ...

The global diabetes care devices market size is calculated at USD 36.45 billion in 2025 and is expected to reach around USD ...